NeoGenomics Inc (NEO)
Solvency ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.82 | 1.79 | 1.74 | 1.69 | 1.42 |
NeoGenomics Inc has consistently maintained a strong solvency position as reflected in its solvency ratios.
The debt-to-assets ratio for NeoGenomics Inc has been consistently 0.00 over the past five years, indicating that the company has not relied on debt to finance its assets during this period. This suggests a low financial risk associated with the company's asset financing.
Similarly, the debt-to-capital ratio and debt-to-equity ratio have also remained at 0.00 throughout the five-year period. These ratios suggest that NeoGenomics Inc has a conservative capital structure with minimal reliance on debt for financing its operations and growth, resulting in a lower risk of financial distress.
The financial leverage ratio has shown a slight increasing trend over the years, from 1.42 in 2020 to 1.82 in 2024. Although the ratio has increased, it still remains at a relatively low level, indicating that the company's financial risk and leverage position are within manageable levels.
Overall, NeoGenomics Inc's solvency ratios demonstrate a strong financial position and effective management of debt levels, which enhances the company's ability to withstand financial challenges and capitalize on future growth opportunities.
Coverage ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Interest coverage | -11.19 | -13.06 | -104.80 | -1.97 | -1.00 |
NeoGenomics Inc's interest coverage ratio has been fluctuating over the years based on the provided data.
As of December 31, 2020, the interest coverage ratio was -1.00, indicating that the company's earnings before interest and taxes (EBIT) were not sufficient to cover its interest expenses, which is a concerning sign as it implies financial distress.
By December 31, 2021, the interest coverage ratio declined further to -1.97, suggesting a continued inability to meet interest obligations from operating profits.
The ratio significantly deteriorated by December 31, 2022, reaching -104.80, indicating a severe financial strain as the company's EBIT was substantially insufficient to cover interest payments.
Although there was some improvement by December 31, 2023, with the interest coverage ratio at -13.06, it still points to a situation where the company is struggling to generate enough earnings to cover its interest expenses.
By December 31, 2024, the interest coverage ratio remained negative at -11.19, indicating that the company's financial position continues to be challenging in terms of meeting interest obligations from its operating profits.
Overall, the trend of negative interest coverage ratios over the years suggests that NeoGenomics Inc has been facing difficulties in generating enough profits to cover its interest expenses, which may raise concerns about its financial stability and ability to service its debt obligations. Further analysis of the company's financial health and strategies to improve its profitability and operational efficiency may be warranted.